Oritavancin is a novel semisynthetic glycopeptide antibiotics. On August 6, 2014, the FDA approved oritavancin for treatment of skin infections. Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci.

171099-57-3

C86H97Cl3N10O26

1793.12

DMSO:Soluble
Powder: -20°C for 3 years
In solvent: -80°C for 2 years